175 related articles for article (PubMed ID: 21127316)
1. Predicting EQ-5D utility scores from the Seattle Angina Questionnaire in coronary artery disease: a mapping algorithm using a Bayesian framework.
Wijeysundera HC; Tomlinson G; Norris CM; Ghali WA; Ko DT; Krahn MD
Med Decis Making; 2011; 31(3):481-93. PubMed ID: 21127316
[TBL] [Abstract][Full Text] [Related]
2. Mapping the Seattle Angina Questionnaire to EQ-5D-5L in patients with coronary heart disease.
Li C; Dou L; Fu Q; Li S
Health Qual Life Outcomes; 2023 Jul; 21(1):64. PubMed ID: 37400827
[TBL] [Abstract][Full Text] [Related]
3. Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease.
Goldsmith KA; Dyer MT; Buxton MJ; Sharples LD
Health Qual Life Outcomes; 2010 Jun; 8():54. PubMed ID: 20525323
[TBL] [Abstract][Full Text] [Related]
4. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
[TBL] [Abstract][Full Text] [Related]
5. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
Yang Q; Yu XX; Zhang W; Li H
Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
[TBL] [Abstract][Full Text] [Related]
6. Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly.
Badia X; Trainer P; Biermasz NR; Tiemensma J; Carreño A; Roset M; Forsythe A; Webb SM
J Med Econ; 2018 Apr; 21(4):382-389. PubMed ID: 29261359
[TBL] [Abstract][Full Text] [Related]
7. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
8. Conversion of the Seattle Angina Questionnaire into EQ-5D utilities for ischemic heart disease: a systematic review and catalog of the literature.
Wijeysundera HC; Farshchi-Zarabi S; Witteman W; Bennell MC
Clinicoecon Outcomes Res; 2014; 6():253-68. PubMed ID: 24876788
[TBL] [Abstract][Full Text] [Related]
9. Kidney Function Does Not Modify the Favorable Quality of Life Changes Associated With Revascularization for Coronary Artery Disease: Cohort Study.
James MT; Wilton SB; Clement FM; Ghali WA; Knudtson ML; Tan Z; Tonelli M; Hemmelgarn BR; Norris CM;
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27436303
[TBL] [Abstract][Full Text] [Related]
10. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
Pullenayegum EM; Chan KK; Xie F
Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
[TBL] [Abstract][Full Text] [Related]
11. Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating.
Thompson NR; Lapin BR; Katzan IL
Pharmacoeconomics; 2017 Nov; 35(11):1167-1176. PubMed ID: 28710740
[TBL] [Abstract][Full Text] [Related]
12. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
13. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
[TBL] [Abstract][Full Text] [Related]
14. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
Kay S; Ferreira A
Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
[TBL] [Abstract][Full Text] [Related]
15. Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches.
Acaster S; Pinder B; Mukuria C; Copans A
Health Qual Life Outcomes; 2015 Mar; 13():33. PubMed ID: 25879833
[TBL] [Abstract][Full Text] [Related]
16. Mapping the COPD Assessment Test onto EQ-5D.
Hoyle CK; Tabberer M; Brooks J
Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
[TBL] [Abstract][Full Text] [Related]
17. Bayesian statistical models to estimate EQ-5D utility scores from EORTC QLQ data in myeloma.
Kharroubi SA; Edlin R; Meads D; McCabe C
Pharm Stat; 2018 Jul; 17(4):358-371. PubMed ID: 29460413
[TBL] [Abstract][Full Text] [Related]
18. Mapping study of papillary thyroid carcinoma in China: Predicting EQ-5D-5L utility values from FACT-H&N.
Huang D; Peng J; Chen N; Yang Q; Jiang L
Front Public Health; 2023; 11():1076879. PubMed ID: 36908441
[TBL] [Abstract][Full Text] [Related]
19. Mapping a patient-reported functional outcome measure to a utility measure for comparative effectiveness and economic evaluations in older adults with low back pain.
Rundell SD; Bresnahan BW; Heagerty PJ; Comstock BA; Friedly JL; Jarvik JG; Sullivan SD
Med Decis Making; 2014 Oct; 34(7):873-83. PubMed ID: 24829274
[TBL] [Abstract][Full Text] [Related]
20. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
